前收市價 | 28.00 |
開市 | 28.00 |
買盤 | 0.00 |
賣出價 | 0.00 |
拍板 | 115.00 |
到期日 | 2024-06-21 |
今日波幅 | 28.00 - 28.00 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 21 |
Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions. And their stocks show potential to soar upon Food and Drug Administration (FDA) approval and public market release. This excellent opportunity that biotech stocks present can provide investors with potentially exponential returns. Let’s learn about these three biotech stocks and
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.